Baihual Pharmaceuticals: Six consecutive trading days of the upper limit, with an increase of 77.07%, not involved in innovative drug research and development.

Baohua Pharmaceuticals announced that its stock has hit the daily limit up for six consecutive trading days from August 4 to August 11, 2026, with an increase of 77.07%. The company has issued a stock trading risk warning. Baohua is a CRO company primarily engaged in the R&D of small molecule generic drugs and does not involve the R&D of innovative drugs. There have been no significant changes in its main business. In the first quarter of 2026, the company reported operating revenue of 67.1829 million yuan, a year-on-year decrease of 30.68%; the net profit attributable to shareholders of the listed company was 6.6427 million yuan, a year-on-year decrease of 67.94%. The company's latest rolling price-to-earnings ratio is 184.25 times, while the rolling price-to-earnings ratio for the industry is 34.96 times.